Objective:

To evaluate the applicability of Canadian treat-to-target (T2T) recommendations for moderate-to-severe atopic dermatitis in real-world practice.

Approach:

Key Findings:

• Achieving or missing treatment targets was generally aligned with decisions to continue or modify treatment.
• The study involved 297 patients treated with dupilumab, tralokinumab, or JAK inhibitors.
• 203 patients remained on treatment for one year or longer.

Interpretation:

Limitations:

• The study was retrospective and may be subject to biases inherent in chart reviews.
• Patients treated as part of clinical trials were excluded, potentially limiting generalizability.

Conclusion:

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.